Previous 10 | Next 10 |
2023-09-05 05:54:13 ET Related stocks stories Compare metrics for ABNB to BX, MANU Airbnb: S&P 500 Addition Strengthens Its Robust Growth Story Manchester United: Assessing Takeover Potential Amid Market Buzz Blackstone: Load Up Before It Recovers Its All...
SHANGHAI, China and CAMBRIDGE, Mass., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) granted Breakthrough Therapy Designation for investigational repotrec...
2023-08-08 15:15:17 ET Zai Lab Limited. (ZLAB) Q2 2023 Earnings Conference Call August 8, 2023 8:00 AM ET Company Participants Christine Chiou - Senior Vice President of Investor Relations Yajing Chen - Chief Financial Officer Samantha Du - Founder, Chairperson a...
2023-08-08 14:20:40 ET More on NovoCure NovoCure: Uncertain Regulatory Path And Slowing Growth NovoCure At 5 Year Lows: Avoid Or Opportunity? NovoCure upgraded at Wedbush citing balanced risk-reward setup Why did NovoCure stock crash today? TTFields data ...
2023-08-07 16:42:20 ET Zai Lab press release ( NASDAQ: ZLAB ): Q2 GAAP EPS of -$1.25 misses by $0.50 . Revenue of $68.86M (+43.0% Y/Y) misses by $1.81M . For further details see: Zai Lab GAAP EPS of -$1.25 misses by $0.50, revenue of $68.86M misses by $1.81M
Total product revenue of $68.9 million for the second quarter of 2023, representing 45% y-o-y growth; 53% y-o-y growth at constant exchange rate VYVGART ® (efgartigimod alfa injection) approved in China as first-and-only neonatal Fc receptor (FcRn) blocker for general...
2023-08-03 11:40:42 ET Summary On August 2, Blueprint Medicines, a pharmaceutical company developing medicines for treating cancer and blood diseases, released its financial results for the second quarter of 2023. Blueprint Medicines' revenue for the second quarter of 2023 was $57...
2023-07-26 23:36:47 ET Summary Zai Lab Limited's recent clinical study results and partnerships demonstrate its commitment to innovation and product development, positioning it as a strong investment prospect in the pharmaceutical industry. The company's partnership with MediLink ...
SHANGHAI, China and CAMBRIDGE, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report financial results for the second quarter of 2023 and recent corporate updates, after the closing of the U.S. equity markets on August 7, 2023. The...
The Phase 3 PRIME study demonstrates that treatment with ZEJULA significantly extends progression-free survival versus placebo and reduces the risk of disease progression or death by 55% Findings confirm the benefit of ZEJULA monotherapy as first-line maintenance treatment, regardle...
News, Short Squeeze, Breakout and More Instantly...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study Zai Lab Limited (NASDAQ: Z...
Manuscript represents the first publication from China’s gynecology oncology field to be published in Cell Publication highlights first-time learnings about the landscape of ovarian cancer microenvironment stratified by HRD and how a PARP inhibitor perturbs it Data suggest ...
2024-07-05 18:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...